CRITICAL PHARMACEUTICALS LIMITED

Their core work

Critical Pharmaceuticals is a Nottingham-based pharmaceutical SME specializing in advanced drug delivery systems, with a documented focus on sustained-release formulations for ocular therapeutics. Their flagship development — explored through the STROBE project — involves creating a depot formulation of bevacizumab (an anti-VEGF monoclonal antibody) for intravitreal administration to treat wet age-related macular degeneration, addressing the clinical burden of frequent eye injections. Their participation in the SUSPOL doctoral network on organocatalysis and sustainable polymers suggests they also draw on polymer chemistry as a foundational platform for their delivery systems. As a small company with SME Instrument funding, they translate academic formulation science into commercially viable pharmaceutical products.

What they specialise in

How they've shifted over time

Both H2020 projects date from 2015, so no genuine temporal evolution can be traced from available data. At that point, the company was simultaneously pursuing a commercial development path (STROBE, SME Instrument Phase 1 feasibility) and building academic connections in polymer chemistry (SUSPOL, MSCA doctoral network). No keyword metadata exists to detect any later shift in priorities. The profile is a single-period snapshot, not a trajectory.

With data limited to 2015, direction cannot be confirmed, but the pairing of a commercial feasibility grant (STROBE) with a polymer science doctoral network (SUSPOL) suggests a company building a polymer-based platform specifically for sustained biologic delivery in ophthalmology.

How they like to work

Critical Pharmaceuticals has taken both a leadership role — coordinating STROBE as an SME-1 applicant — and a supporting partner role in the large SUSPOL academic consortium. Their ability to lead a small commercial feasibility project while simultaneously contributing industrial expertise to an MSCA doctoral programme suggests flexibility across project types. With 9 documented partners, their network is modest in size but cross-national in reach.

Their documented H2020 network spans 9 unique partners across 7 countries, consistent with a small SME in early-stage EU participation. The geographic spread reflects genuine European engagement despite the limited project volume.

What sets them apart

Critical Pharmaceuticals occupies a narrow but commercially significant niche: sustained-release formulation of biologics for intravitreal use, targeting one of the largest unmet needs in ophthalmology. Few SMEs combine pharmaceutical formulation expertise with the specific technical challenge of delivering monoclonal antibodies inside the eye. Their SME Instrument coordination indicates they hold proprietary technology and are pursuing commercialization, not simply offering contract services.

Highlights from their portfolio

• STROBE
  Coordinated as SME lead under the SME Instrument, this feasibility study targets wet AMD — a major global ophthalmic market — with a bevacizumab sustained-release depot that could eliminate the need for monthly injections.
• SUSPOL
  Participation in a competitive MSCA European Joint Doctorate on organocatalysis and sustainable polymers demonstrates academic-level engagement with the polymer science that likely underpins their delivery platform.